Free shipping on all orders over $ 500

Sintilimab

Cat. No. M24902

All AbMole products are for research use only, cannot be used for human consumption.

Sintilimab Structure
Synonym:

IBI308

Size Price Availability
1mg USD 200  USD200 3-4 Weeks
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.

Chemical Information
CAS Number 2072873-06-2
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Shun Lu, et al. Lancet Oncol. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-bli䲧瘀Ỵ瘁㧀痿羹皘的㸈ܯ

[2] Zhihao Lu, et al. BMJ. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

[3] Lin Zhang, et al. Biomark Res. Sintilimab for the treatment of non-small cell lung cancer

[4] Zhenggang Ren, et al. Lancet Oncol. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

[5] Lin Zhang, et al. Front Oncol. Sintilimab: A Promising Anti-Tumor PD-1 Antibody

Related PD-1/PD-L1 Products
PD-1/PD-L1-IN-9

PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.

NSC622608 

NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM.

PD-L1-IN-1 

PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM.

SL-279252

SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours.

Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

  Catalog
Abmole Inhibitor Catalog




Keywords: Sintilimab, IBI308 supplier, PD-1/PD-L1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.